Ken Cacciatore
Stock Analyst at TD Cowen
(0.30)
# 4,252
Out of 4,975 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $17.15 | +191.55% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $7.35 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $15.40 | +29.87% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $5.57 | +348.83% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $15.01 | +133.18% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.58 | +1,296.65% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $3.14 | +1,492.36% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $15.87 | +183.55% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $15.38 | +2,890.90% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $17.15
Upside: +191.55%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.35
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $15.40
Upside: +29.87%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $5.57
Upside: +348.83%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $15.01
Upside: +133.18%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.58
Upside: +1,296.65%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $3.14
Upside: +1,492.36%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $15.87
Upside: +183.55%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $15.38
Upside: +2,890.90%